Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2013

Jun 14, 2013

33651_dirs_2013-06-13_8ddd539d-7dae-4909-bede-8ccf61a45993.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-06-04

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-06-04 Common Stock A 9327 Acquired 145703 Direct

Footnotes

F1: The shares acquired were issued for the account of the reporting person at a value of $2.60 per share in payment of contingent value rights held by the reporting person.